Literature DB >> 20566631

Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line.

Florian Schelter1, Michael Gerg, Birgit Halbgewachs, Susanne Schaten, Agnes Görlach, Florian Schrötzlmair, Achim Krüger.   

Abstract

During tumor progression, malignant cells must repeatedly survive microenvironmental stress. Hypoxia-inducible factor-1 (HIF-1) signaling has emerged as one major pathway allowing cellular adaptation to stress. Recent findings led to the hypothesis that HIF-1alpha may enhance the metastatic potential of tumor cells by a survival-independent mechanism. So far it has not been shown that HIF-1alpha also directly regulates invasive processes during metastasis in addition to conferring a survival advantage to metastasizing tumor cells. In a hypoxia-tolerant tumor cell line (L-CI.5s), which did not rely on HIF-1 signaling for viability in vitro and in vivo, knockdown of Hif-1alpha reduced invasiveness of the tumor cells in vitro as well as extravasation and secondary infiltration in vivo. Liver metastases associated induction of proinvasive receptor tyrosine kinase Met phosphorylation as well as gelatinolytic activity were Hif-1alpha-dependent. Indeed, promoter activity of the matrix metalloproteinase-9 (mmp-9) was shown to be Hif-1alpha-dependent. This study uncovers a new survival-independent biological function of HIF-1alpha contributing to the efficacy of metastases formation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566631      PMCID: PMC2924026          DOI: 10.1074/jbc.M110.140608

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  siRNA targeting HIF-1alpha induces apoptosis of pancreatic cancer cells through NF-kappaB-independent and -dependent pathways under hypoxic conditions.

Authors:  Chuangui Chen; Zhentao Yu
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

2.  Desferrioxamine enhances hypoxic ventilatory response and induces tyrosine hydroxylase gene expression in the rat brainstem in vivo.

Authors:  M V C Nguyen; S Pouvreau; F Z El Hajjaji; M Denavit-Saubie; J M Pequignot
Journal:  J Neurosci Res       Date:  2007-04       Impact factor: 4.164

Review 3.  Functional genetic mouse models: promising tools for investigation of the proteolytic internet.

Authors:  Achim Krüger
Journal:  Biol Chem       Date:  2009-02       Impact factor: 3.915

Review 4.  Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas.

Authors:  Daniela Furlan; Nora Sahnane; Ileana Carnevali; Roberta Cerutti; Silvia Uccella; Valentina Bertolini; Anna Maria Chiaravalli; Carlo Capella
Journal:  Surg Oncol       Date:  2007-11-26       Impact factor: 3.279

5.  Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases.

Authors:  Michael Gerg; Charlotte Kopitz; Susanne Schaten; Alexander Tschukes; Christoph Kahlert; Manfred Stangl; Claus W Hann von Weyhern; Björn L D M Brücher; Dylan R Edwards; Karsten Brand; Achim Krüger
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

6.  Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment.

Authors:  D Lee Gorden; Barbara Fingleton; Howard C Crawford; Duco E Jansen; Martin Lepage; Lynn M Matrisian
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

Review 7.  The role of hypoxia-inducible factors in tumorigenesis.

Authors:  E B Rankin; A J Giaccia
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

Review 8.  The MET receptor tyrosine kinase in invasion and metastasis.

Authors:  Silvia Benvenuti; Paolo M Comoglio
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

Review 9.  The impact of O2 availability on human cancer.

Authors:  Jessica A Bertout; Shetal A Patel; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2008-11-06       Impact factor: 60.716

10.  Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

Authors:  Charlotte Kopitz; Michael Gerg; Obul Reddy Bandapalli; Dilek Ister; Caroline J Pennington; Stephanie Hauser; Christin Flechsig; Hans-Willi Krell; Dalibor Antolovic; Keith Brew; Hideaki Nagase; Manfred Stangl; Claus W Hann von Weyhern; Björn L D M Brücher; Karsten Brand; Lisa M Coussens; Dylan R Edwards; Achim Krüger
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

View more
  9 in total

1.  Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α.

Authors:  Florian Schelter; Birgit Halbgewachs; Petra Bäumler; Caroline Neu; Agnes Görlach; Florian Schrötzlmair; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2010-10-30       Impact factor: 5.150

Review 2.  Molecular targets and pathways involved in liver metastasis of colorectal cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2015-06-24       Impact factor: 5.150

3.  Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.

Authors:  Florian Schelter; Martina Grandl; Bastian Seubert; Susanne Schaten; Stephanie Hauser; Michael Gerg; Carla Boccaccio; Paolo Comoglio; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2011-07-26       Impact factor: 5.150

4.  Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

Authors:  Jiyoung Mun; Adnan Abdul Jabbar; Narra Sarojini Devi; Shaoman Yin; Yingzhe Wang; Chalet Tan; Deborah Culver; James P Snyder; Erwin G Van Meir; Mark M Goodman
Journal:  J Med Chem       Date:  2012-07-24       Impact factor: 7.446

5.  On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210.

Authors:  Haissi Cui; Sebastien Grosso; Florian Schelter; Bernard Mari; Achim Krüger
Journal:  Front Pharmacol       Date:  2012-07-12       Impact factor: 5.810

6.  Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor.

Authors:  Georgia A McCann; Shan Naidu; Kellie S Rath; Hemant K Bid; Brent J Tierney; Adrian Suarez; Saradhadevi Varadharaj; Jianying Zhang; Kálmán Hideg; Peter Houghton; Periannan Kuppusamy; David E Cohn; Karuppaiyah Selvendiran
Journal:  Oncoscience       Date:  2014-03-31

7.  PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization.

Authors:  Shuai Wang; Fa-Ji Yang; Xun Wang; Yuan Zhou; Bo Dai; Bing Han; Hu-Cheng Ma; Yi-Tao Ding; Xiao-Lei Shi
Journal:  Oncotarget       Date:  2017-10-04

Review 8.  Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.

Authors:  Wenjie Liang; Yicheng Ni; Feng Chen
Journal:  Oncotarget       Date:  2016-03-29

9.  IRAG2 Interacts with IP3-Receptor Types 1, 2, and 3 and Regulates Intracellular Ca2+ in Murine Pancreatic Acinar Cells.

Authors:  Sally Prüschenk; Michael Majer; Rainer Schreiber; Jens Schlossmann
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.